Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP

Journal of the National Cancer Institute

Volumn 99, Issue 24, 2007, Pages 1836-1844

  Duggan, David ^a   Zheng, Siqun L ^b   Knowlton, Michele ^a   Benitez, Debbie ^a   Dimitrov, Latchezar ^b   Wiklund, Fredrik ^c   Robbins, Christiane ^a   Isaacs, Sarah D ^d   Cheng, Yu ^b   Li, Ge ^b   Sun, Jielin ^b   Chang, Bao Li ^b   Marovich, Leslie ^a   Wiley, Kathleen E ^d   Bälter, Katarina ^c   Stattin, Pär ^e   Adami, Hans Olov ^c,f   Gielzak, Marta ^d   Yan, Guifang ^d   Sauvageot, Jurga ^d   Liu, Wennuan ^b   Kim, Jin Woo ^b   Bleecker, Eugene R ^b   Meyers, Deborah A ^b   Trock, Bruce J ^d   Partin, Alan W ^d   Walsh, Patrick C ^d   Isaacs, William B ^d,h   Grönberg, Henrik ^c   Xu, Jianfeng ^b,g   Carpten, John D ^a   more..

^a TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c KAROLINSKA INSTITUTE   (Sweden)

^d DEPARTMENT OF PATHOLOGY   (United States)

^e UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^f HARVARD UNIVERSITY   (United States)

^g Medical Center Blvd   (United States)

^h JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; DAB2IP PROTEIN, HUMAN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AFRICAN AMERICAN; AGED; ALLELE; ARTICLE; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; DAB2IP GENE; GENE; GENE LOCATION; GENETIC ASSOCIATION; GENETIC CODE; GENETIC MARKER; GENETIC MODEL; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; PROSTATE CANCER; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE; SUPPRESSOR GENE; SWEDEN; CAUCASIAN; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; MIDDLE AGED; PROSTATE TUMOR; RISK; RISK ASSESSMENT; RISK FACTOR; TUMOR SUPPRESSOR GENE;

AFRICAN AMERICANS; AGED; CASE-CONTROL STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENES, TUMOR SUPPRESSOR; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; RAS GTPASE-ACTIVATING PROTEINS; RISK ASSESSMENT; RISK FACTORS; SWEDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 38449103390     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djm250     Document Type: Article

References (23)

1. Isaacs WB, Xu J, Walsh PC. Hereditary prostate cancer. In: Chung LWK, Isaacs WB, Simons JW, editors. Prostate cancer, biology, genetics, and the new therapeutics. Totowa (NJ): Humana Press; 2001. p. 13-28.
2. Gudmundsson J, Sulem P, Manolescu A, Amundadottir LT, Gudbjartsson D, Helgason A, et al. Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet 2007;39:631-7.
3. Yeager M, Orr N, Hayes RB, Jacobs KB, Kraft P, Wacholder S, et al. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet 2007;39:645-9.
4. Zheng SL, Augustsson-Balter K, Chang B, Hedelin M, Li L, Adami HO, et al. Sequence variants of toll-like receptor 4 are associated with prostate cancer risk: results from the Cancer Prostate in Sweden Study. Cancer Res 2004;64:2918-22.
5. Mostofi FK, Sesterhenn I, Sobin LH, editors. Histological typing of prostate tumours. Geneva (Switzerland): World Health Organization; 1982. p. 15-23.
6. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL; ISUP Grading Committee. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma [review]. Am J Surg Pathol 2005;29:1228-42.
7. Amundadottir LT, Sulem P, Gudmundsson J, Helgason A, Baker A, Agnarsson BA, et al. A common variant associated with prostate cancer in European and African populations. Nat Genet 2006;38:652-8.
8. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005;21:263-5.
9. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719-48.
10. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 2002;70:425-34.
11. Pritchard JK, Stephens M, Rosenberg NA, Donnelly P. Association mapping in structured populations. Am J Hum Genet 2000;67:170-81.
12. Clayton DG, Walker NM, Smyth DJ, Pask R, Cooper JD, Maier LM, et al. Population structure, differential bias and genomic control in a large-scale, case-control association study. Nat Genet 2005;37:1243-6.
13. Kruglyak L, Nickerson DA. Variation is the spice of life. Nat Genet 2001;27:234-6.
14. Wang Z, Tseng CP, Pong RC, Chen H, McConnell JD, Navone N, et al. The mechanism of growth-inhibitory effect of DOC-2/DAB2 in prostate cancer. Characterization of a novel GTPase-activating protein associated with N-terminal domain of DOC-2/DAB2. J Biol Chem 2002;277:12622-31.
15. Chen H, Pong RC, Wang Z, Hsieh JT. Differential regulation of the human gene DAB2IP in normal and malignant prostatic epithelia: cloning and characterization. Genomics 2002;79:573-81.
16. Chen H, Toyooka S, Gazdar AF, Hsieh JT. Epigenetic regulation of a novel tumor suppressor gene (hDAB2IP) in prostate cancer cell lines. J Biol Chem 2003;278:3121-30.
17. Chen H, Tu SW, Hsieh JT. Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer. J Biol Chem 2005;280:22437-44.
18. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002;419:624-9.
19. Yano M, Toyooka S, Tsukuda K, Dote H, Ouchida M, Hanabata T, et al. Aberrant promoter methylation of human DAB2 interactive protein (hDAB2IP) gene in lung cancers. Int J Cancer 2005;113:59-66.
20. Vire E, Brenner C, Deplus R, Blanchon L, Fraga M, Didelot C, et al. The polycomb group protein EZH2 directly controls DNA methylation. Nature 2006;439:871-4.
21. Zhang R, He X, Liu W, Lu M, Hsieh JT, Min W. AIP1 mediates TNF-alpha-induced ASK1 activation by facilitating dissociation of ASK1 from its inhibitor 14-3-3. J Clin Invest 2003;111:1933-43.
22. Zhang H, Zhang R, Luo Y, D'Alessio A, Pober JS, Min W. AIP1/DAB2IP, a novel member of the Ras-GAP family, transduces TRAF2-induced ASK1-JNK activation. J Biol Chem 2004;279:44955-65.
23. von Bergh AR, Wijers PM, Groot AJ, van Zelderen-Bhola S, Falkenburg JH, Kluin PM, et al. Identification of a novel RAS GTPase-activating protein (RASGAP) gene at 9q34 as an MLL fusion partner in a patient with de novo acute myeloid leukemia. Genes Chromosomes Cancer 2004;39:324-34.